Monthly Archives: July 2009

Pharma companies looking to Womens Health for growth

July 29th, 2009|

During menopause, women experience many symptoms associated with the natural change in hormone levels. Hot flashes and sexual dysfunction are the most prevalent symptoms, and if untreated can lead to sleep deprivation and even depression.

Aurobindo Pharma gets tentative USFDA nod for Alzheimer drug

July 28th, 2009|

Drug maker, Aurobindo Pharma (Q,N,C,F)* has received the tentative approval for Donepezil Hydrochloride Tablets 5 mg and 10 mg (ANDA 90-056) from the US Food & Drug Administration (USFDA).

FDA Heat Fails to Scorch Appeal of Indian Pharma

July 28th, 2009|

Some Indian pharmaceutical companies are facing increased regulatory scrutiny in developed markets and that's perking up the view on the sector.

Genentech Announces Appointment of Sandra J. Horning, M.D., to Senior Vice President, Global Head

July 27th, 2009|

Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the appointment of Sandra J. Horning, M.D., to senior vice president, global head, Clinical Development Hematology/Oncology.

Frost & Sullivans Food & Beverage Focus 2009

July 23rd, 2009|

Growing awareness and increased investments lead to growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements sector, reveals Frost & Sullivan

Baring India to tap SME pharma space to fund inorganic growth opportunities.

July 23rd, 2009|

Baring Private Equity Partners India intends to finance the inorganic growth opportunities in the small-medium enterprises (SME) of the pharma sector.

A Patently Good Idea

July 23rd, 2009|

Despite arguments from the pharma sector that the use of patents is a vital and necessary means of protecting revenue, many of the worst affected in a health crisis would simply be unable to afford potentially life-saving medication in the absence of alternatives offered by generic drug companies.

Exploit more, explore less is Dr Reddys strategy in tough conditions

July 23rd, 2009|

‘Exploit’ more and ‘explore’ less. This has been the strategy of the Rs 6,944-crore pharma major, Dr Reddy’s Laboratories, to face challenges thrown up by the global economic slowdown.

Pharma cos may show a mixed bag in Q1

July 19th, 2009|

The first quarter performance for the pharma sector is expected to be a mixed bag. There are certain positives in the form of lower input prices, one-time incomes for certain companies and recovery in the global economic situation.

Teva Pharma recalls anti-anxiety drug Propofol

July 19th, 2009|

US drug maker Teva Pharmaceuticals has voluntarily recalled Propofol Injectable — a drug used in the treatment of anxiety — following incidents of side effects on patients.

Xeloda-Oxaliplatin Combination (Xelox) Shown to Be More Effective Than Standard Chemotherapy Regime

July 18th, 2009|

Genentech, Inc. announced today that an international Phase III study demonstrated that oral Xeloda® plus oxaliplatin (XELOX) is superior to a commonly used intravenous chemotherapy, 5-FU/LV (infused 5-fluorouracil plus leucovorin), in increasing the time people with adjuvant colon cancer lived without their cancer returning when given immediately after surgery.

Watson seeks US FDA marketing nod for generic Sanctura XR

July 16th, 2009|

Watson Pharma, a leading specialty pharmaceutical company, confirmed that its subsidiary, Watson Laboratories, Inc-Florida (Watson), has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration seeking approval to market its trospium chloride extended-release 60 mg capsules prior to the expiration of a patent owned by Supernus Pharmaceuticals, Inc.

Strong dollar beats down pharma revenues

July 15th, 2009|

It's that time again: Earnings time. As you know, Johnson & Johnson and Abbott Laboratories reported earlier this week; today we have Baxter, Novartis, and Biogen Idec. So far it looks like a tough quarter for sales, with currency costs holding down revenues at some companies and new generic competition eating into others.  

Indian pharma firm sets up subsidiary in Romania

July 15th, 2009|

JB Chemicals and Pharmaceuticals, an Indian drug maker, has established a wholly-owned subsidiary in Romania as a stepping stone to expansion in the Central and Eastern Europe (CEE) region, Pharmabiz.com reported. The move reflects the company's conviction that there is a high potential for herbal and ethical formulations in CEE.

Evotec enters fragment-based drug discovery pact with Cubist Pharma

July 15th, 2009|

Evotec AG, a leading provider in the discovery and development of novel small molecule drugs, announced that it has entered into a research agreement with Cubist Pharmaceuticals, Inc., a leading acute care biopharmaceutical company located in Lexington, Massachusetts, USA.

Dabur eyes acquisitions up to Rs 500 cr in healthcare

July 15th, 2009|

Fast moving consumer goods (FMCG) company Dabur is planning to acquire more companies in the healthcare segment in India and could spend up to Rs 500 crore for the buyouts. The move follows the recent acquisition of Fem Care Pharma for over Rs 250 crore.

SciGen a big winner in human insulin deal with Bayer Schering Pharma AG

July 15th, 2009|

In a major win for SciGen (ASX: SIE) – details have emerged of the exclusive supply and distribution agreement inked with by its holding company, Bioton SA – with major pharmaceutical company Bayer Schering Pharma AG.

The first largest pharma deal of the year: Advent buys Ozone

July 15th, 2009|

Advent International, a buyout firm based in US that holds local drug maker LaborMed is on the verge of taking over Ozone’s product array, without sharing any financial details of the deal.

Pharma Accused of Keeping Good Generics Down

July 15th, 2009|

The European Commission has accused the pharmaceutical industry of delaying the entry of generic drugs to the market. As a result, it intends to step up its scrutiny of the sector under EU antitrust law. “We must have more competition and less red tape in pharmaceuticals,” claimed Competition Commissioner Neelie Kroes.

Israel ranks high in counterfeit pharmaceutical trade

July 15th, 2009|

We're on the map, but the wrong map: In 2008 Israel ranked eighth in the world's counterfeit pharmaceuticals trade, with 78 reported cases of fake drugs worth up to NIS 100 million. And those were only the cases that were caught.